Timothy Anderson said the US cholesterol guidelines for statins now move preventive treatment toward younger, lower-risk adults, after a 2026 guideline expanded who can qualify for lipid-lowering therapy. Based on NHANES cycles 2017-2023, 21.5 million nonpregnant U.S. adults age 30-79 years were newly statin eligible.
Anderson, a MD, MAS at the University of Pittsburgh, said: "The 2026 dyslipidemia guideline substantially expands the U.S. population recommended for primary prevention statin therapy, predominantly in lower-risk individuals". He also said: "The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients".
PREVENT and 87.5 million
The guideline now uses PREVENT equations to guide primary prevention decisions. Lipid-lowering therapy can be considered at a 10-year PREVENT-ASCVD risk estimate of 3% to less than 5%, and it should be considered at 5% to less than 10%.
Using NHANES cycles 2017-2023, the estimate of statin-eligible nonpregnant U.S. adults age 30-79 years rose to 87.5 million. The newly statin-eligible group was younger and lower risk than adults previously recommended statin therapy, with a mean estimated 10-year ASCVD risk of 3.1% versus 6.1% for those previously recommended treatment.
JAMA and the risk shift
Anderson reported in JAMA that the updated guideline substantially expands primary prevention statin therapy in lower-risk individuals. He said that before the new guidelines, people flagged with high cholesterol in their 30s and 40s tended to be recommended to focus on diet and exercise and were not recommended medication unless they already had heart disease or other factors that made them particularly high-risk, like diabetes.
A separate analysis projected that the new guideline reclassifies over one in five adults based on the PREVENT equations. Two-thirds of those reassigned adults were moved to lower-risk categories and one-third were moved to higher-risk categories, with men, Black individuals and current smokers more often shifted downward and women and individuals with diabetes more often shifted upward.
Allison Peng in Baltimore
Allison Peng of Johns Hopkins University School of Medicine in Baltimore wrote that there was no significant net change in statin recommendation, adding: "Notably, there was no significant net change in statin recommendation, suggesting that risk recalibration with PREVENT-ASCVD does not translate into fewer people recommended for evidence-based preventive therapy at the population level,".
That second NHANES analysis used adults age 40-79 years and data from 1999-2020, and it found the share who may be recommended lipid-lowering therapy was 49.6% with the 2026 guideline versus 49.4% before the guideline. For clinicians, the practical change is not a simple across-the-board expansion; the PREVENT calculation shifts many patients between risk bands, so the decision now depends more on the specific 10-year estimate than on age alone.
The unresolved question is how individual clinicians will apply the lower PREVENT thresholds to younger adults in routine practice, especially when the same guideline broadens eligibility yet one analysis found almost no net change at the population level.
